Supernus Pharmaceuticals (NASDAQ:SUPN)

CAPS Rating: 2 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar mirqce (< 20) Submitted: 11/21/2014 7:24:48 PM : Outperform Start Price: $8.94 SUPN Score: -3.86

two new drugs two more in pipe line low debt some cash good management

Recs

0
Member Avatar manirg (71.51) Submitted: 8/13/2014 4:22:36 PM : Outperform Start Price: $9.03 SUPN Score: -10.28

low valuation

Recs

0
Member Avatar cavemantrader (47.55) Submitted: 12/24/2013 10:58:05 AM : Outperform Start Price: $8.69 SUPN Score: -14.56

The FDA approved United Therapeutics' drug Orenitram Friday evening. The drug is intended to treat pulmonary arterial hypertension. This could bring SUPN at least 250 million going forward, yet the stock barely moved to the upside. It appears a large number of funds were not expecting the extremely positive development and were shorting the stock, but after some fund manipulation to cover and mitigate losses, expect shares to breakout to the double digits in the near term.

Recs

0
Member Avatar ptanabe (78.87) Submitted: 7/31/2013 6:46:48 PM : Outperform Start Price: $6.87 SUPN Score: +3.29

k

Recs

1
Member Avatar zzlangerhans (99.85) Submitted: 2/27/2013 1:10:38 AM : Outperform Start Price: $7.46 SUPN Score: -23.05

Supernus seems to have stabilized following a nasty below-market dilutive financing in November, so I'll extend a green thumb gingerly based on optimism for the Oxtellar XR launch. Extended release seems like a sufficient advantage to take significant market share from generic oxcarbazepine. After Oxtellar XR, however, the road appears much more rocky. Trokendi SR has been approved "conditionally", but it remains somewhat unclear exactly what the conditions are and when the company can expect full approval. Supernus reported positive data from the phase IIb trial of molindone in ADHD aggression but close examination of the data shows no effect at higher dose or in patients weighing less than 30 kg. Those inconsistencies will weigh on the likelihood of success in a phase III trial. Finally, the harsh CRL for United Therapeutics' oral trepostinil removes that potential source of royalty revenue for the foreseeable future.

Needless to say, it appears that Supernus' short-term performance is depending heavily on the Oxtellar XR launch. If the ramp falls short of expectations, look out below.

Recs

0
Member Avatar 21Emoney21 (< 20) Submitted: 10/19/2012 2:27:45 PM : Outperform Start Price: $13.03 SUPN Score: -79.12

Expect to see FDA approval today on new drug

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:35:17 PM : Outperform Start Price: $9.69 SUPN Score: -62.99

PDUFA coming up

Results 1 - 7 of 7

Featured Broker Partners


Advertisement